COVID’s Aftermath: The Accountability Gap

In the years following the COVID-19 pandemic—an event that reshaped the global economy, public health systems, and everyday life—one question has lingered more than any other: who, if anyone, was truly held accountable?

One figure who sits at an unusual intersection of that question is Dr. Eric Donaldson.

Donaldson is not a household name. He wasn’t on television like Anthony Fauci, nor was he a public-facing official. But records show he played a role both in pre-pandemic virology research and in the federal response that followed.

Public FDA documents confirm that Donaldson served as a virology reviewer within the agency’s Center for Drug Evaluation and Research. During the height of the pandemic in 2020, he was directly involved in reviewing remdesivir, one of the first major antiviral treatments authorized for COVID-19.

In fact, FDA summary reviews show that Donaldson’s analysis contributed to recommending approval of the drug, placing him inside the regulatory process during one of the most consequential medical decisions of the pandemic.

At the same time, independent academic profiles list him as a long-time virologist affiliated with the FDA’s Division of Antiviral Products, with extensive research experience in viral infection and emerging diseases.

On its face, that trajectory might seem normal. Scientists move between academia and government all the time. But the broader context is what makes this story harder to ignore.

A System That Investigated Itself

COVID-19 led to millions of deaths worldwide and unprecedented government intervention. Yet, years later, there has been no singular moment of accountability comparable to the scale of the crisis.

Instead, what we see is continuity.

Researchers involved in studying viruses before the pandemic remained embedded in institutions evaluating treatments during and after it. Regulators relied on the same scientific ecosystem that had shaped virology research for decades. And despite congressional hearings, media investigations, and public outrage, no central figure tied to pandemic-era decisions has faced clear legal consequences tied directly to the origins or handling of the crisis.

Even where investigations have occurred—whether into lab safety, funding pathways, or public messaging—they have largely produced reports, not prosecutions.

This is the deeper tension in the Donaldson story.

It is not simply about one scientist working at the FDA. It is about a system in which the boundaries between research, funding, and regulation are tightly interwoven. The same expertise that makes someone qualified to evaluate a drug can also place them within the network that helped shape the scientific landscape leading up to the crisis.

The Accountability Gap

To be clear, there is no public evidence that Donaldson himself engaged in wrongdoing. His documented role at the FDA reflects standard scientific review work.

But that is precisely the point critics raise: the absence of clear individual culpability, even in the face of massive global consequences.

The pandemic exposed a structural reality. When responsibility is distributed across agencies, universities, private companies, and international collaborations, accountability becomes diffuse. No single actor carries the weight of the outcome. And when no one clearly owns the outcome, no one clearly answers for it.

Millions died. Entire economies were disrupted. Civil liberties were reshaped.

Yet the system that governed pandemic research, response, and regulation largely remained intact—and in many cases, staffed by the same experts who were there before it began.

A Question That Hasn’t Gone Away

The story of Eric Donaldson is not explosive on its own. It is quiet, procedural, almost bureaucratic.

But it points to something bigger.

Not a scandal with a single villain, but a structure where accountability is difficult to isolate—and therefore, rarely enforced.

And that may be the most unsettling conclusion of all.